Sotac Pharmaceuticals (NSE:SOTAC) ROCE % : 11.63% (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Sotac Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sotac Pharmaceuticals's annualized ROCE % for the quarter that ended in Sep. 2024 was 11.63%.

Sotac Pharmaceuticals ROCE % Historical Data

The historical data trend for Sotac Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sotac Pharmaceuticals ROCE % Chart

Sotac Pharmaceuticals Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

5.21

-9.23

32.86

12.33

Sotac Pharmaceuticals Quarterly Data
	Mar20	Mar21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial								8.16	17.67	-0.28	11.15	11.63

Sotac Pharmaceuticals ROCE % Calculation

Sotac Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	55.149	/	( ( (736.39 - 458.116)	+	(1053.269 - 437.3) )	/ 2 )
	=	55.149	/	( (278.274	+	615.969)	/ 2 )
	=	55.149	/	447.1215
	=	12.33 %

Sotac Pharmaceuticals's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	72.716	/	( ( (0 - 0)	+	(1155.107 - 529.99) )	/ 1 )
	=	72.716	/	( ( 0	+	625.117 )	/ 1 )
	=	72.716	/	625.117
	=	11.63 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Sotac Pharmaceuticals (NSE:SOTAC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sotac Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Sotac Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sotac Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sotac Pharmaceuticals Ltd (NSE:SOTAC) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

Plot No. PF-21, Near ACME Pharma, Opposite Teva Pharma Sanand GIDC-II, Sanand, Ahmedabad, GJ, IND, 382110

Website

https://www.sotacpharma.com

Sotac Pharmaceuticals Ltd is a pharma manufacturer, specializing in the manufacturing of a wide range of pharmaceutical products such as Non-Beta-Lactam (general) tablets, beta-lactam coated tablets, beta-lactam uncoated tablets, Non-Beta-Lactam (general) capsules, beta-lactam capsules, oral liquid, dry syrup and external preparations such as nasal spray, relief spray, and cream.

Sotac Pharmaceuticals Headlines

No Headlines